DocWire News Editors

DocwireNews

A study presented at the <a href="https://ash.confex.com/ash/2018/webprogram/Paper113283.html">2018 American Society of Hematology Annual Meeting</a> found that the use of an intravenous (IV) rituximab biosimilar resulted in cost savings compared to subcutaneous reference rituximab in a patient with non-Hodgkin lymphoma (NHL).The researchers conducted a time-and-cost simulation analysis for one patient with NHL over the course of six treatment cycles with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) using either standard or rapid-infusion rituximab. The rituximab component of R-CHOP consists of an IV initiation in cycle one followed by IV standard infusion or 90-minute rapid-infusion, or subcutaneous administration in subsequent cycles.The investigators used Q1 2018 average sales prices and 2018 reimbursement rates as listed in the Current Procedural Terminology code set to develop costs of the subcutaneous and the IV reference rituximab products. Costs for the biosimilar were estimated at 15% to 35% discounts from reference rituximab. Patients were classified by body size: small (1.6 m2), average (1.85 m2), and large (21.2 m2).Following the first cycle of IV reference rituximab, switching to the subcutaneous formulation saved 650, 720, and 791 minutes for patients with small, average, and large body sizes, respectively, over the next five cycles compared to continued IV use.Assuming a switch from the IV reference rituximab to the subcutaneous formulation at cycle two, the cost for six cycles of R-CHOP was $54 higher than rapid-infusion but $104 lower than the standard infusion of the IV reference for patients with small body size. For patients with medium body size, the cost of subcutaneous administration was lower than the cost of rapid and standard IV administration ($3,854 and $4,012, respectively). For patients with large body size, the subcutaneous product saved $7,762 and $7,920 versus the two IV infusions.Compared to an IV biosimilar rituximab, the subcutaneous option was more expensive. For patients with small body size, the subcutaneous formulation cost $3,647 to $8,649 more versus standard infusion and $3,805 to $8,807 more versus rapid infusion of the biosimilar. For patients with medium body size, these ranges were $325 to $6,109 and $484 to $6,267 for the two infusions. For patients with large body size, at a biosimilar discount of 25% or greater, subcutaneous administration cost at least $286 more at a standard infusion rate. At a discount of at least 24%, subcutaneous administration cost at least $116 more than the rapid-infusion biosimilar rituximab.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Study Shows Cost Savings with Biosimilar Rituximab

Oncology

A study presented at the 2018 American Society of Hematology Annual Meeting found that the use of an intravenous (IV) rituximab biosimilar resulted in cost savings compared to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe